It has been reported that neither adalimumab, an anti-tumor necrosis factor (anti-TNF) mAb, nor etanercept, a soluble TNF receptor, modified percentages or absolute numbers of circulating CD4+CD25high Treg cells or other Treg phenotypes after being administered for 6 and 12 weeks to patients with RA, regardless of their response [23]. This evidence concerns the gene TNF and rheumatoid arthritis.